Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company has successfully obtained approval for its self-developed "Recombinant Type I α1 Collagen Freeze-Dried Fiber," marking it as the first of its kind in China, with various specifications suitable for facial dermal tissue filling [2] - The recombinant collagen market in China is projected to reach 54.7 billion yuan by 2025, with the medical aesthetics market expected to grow to 7 billion yuan, indicating significant growth potential for the company [3] - The company is positioned as the second domestic enterprise to receive approval for recombinant collagen, allowing it to benefit from industry expansion [3] - The skincare segment is currently facing short-term sales fluctuations but is expected to stabilize and recover through optimized channel structures and strong brand recognition [4] Summary by Sections Medical Aesthetics - The company's recombinant collagen product showcases technical advantages and strengthens its leading position in the market, with a focus on improving skin structure and reducing dynamic wrinkles [3] - The product's unique formulation and research barriers enhance its market competitiveness [3] Skincare Products - Short-term sales have been impacted by a reduction in collaboration with influencers, but the brand's strength and product recognition remain robust [4] - The company aims to recover sales through channel optimization and continued consumer confidence driven by scientific marketing [4] Financial Projections - Revenue forecasts for 2025-2027 are adjusted to 6.917 billion, 8.540 billion, and 10.419 billion yuan respectively, with net profits projected at 2.452 billion, 2.988 billion, and 3.603 billion yuan [5] - The earnings per share (EPS) for the same period are expected to be 2.29, 2.79, and 3.36 yuan, with corresponding price-to-earnings (PE) ratios of 17, 14, and 11 times [5][8]
巨子生物（02367）：成功获批重组胶原三类械，医美与护肤品共振打开长期空间